Differences
This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revision | ||
wikitox:cholinergictoxicity [2025/02/16 16:49] – kharris | wikitox:cholinergictoxicity [2025/02/17 00:33] (current) – kharris | ||
---|---|---|---|
Line 1: | Line 1: | ||
- | < | + | ====== |
- | + | ||
- | ---- | + | |
===== Introduction ===== | ===== Introduction ===== | ||
Line 9: | Line 7: | ||
===== Mechanism of Toxic Effects ===== | ===== Mechanism of Toxic Effects ===== | ||
- | |||
- | ---- | ||
Cholinergic toxicity occurs when there is excess acetylcholine activity in the body. This can occur from decreased breakdown of acetylcholine due to the presence of acetylcholinesterase inhibitors or direct stimulation by acetylcholine receptor agonists. | Cholinergic toxicity occurs when there is excess acetylcholine activity in the body. This can occur from decreased breakdown of acetylcholine due to the presence of acetylcholinesterase inhibitors or direct stimulation by acetylcholine receptor agonists. | ||
Line 17: | Line 13: | ||
===== Cholinergic agents ===== | ===== Cholinergic agents ===== | ||
- | |||
- | ---- | ||
**Acetylcholinesterase Inhibitors (effect both muscarinic and nicotinic system) include:** | **Acetylcholinesterase Inhibitors (effect both muscarinic and nicotinic system) include:** | ||
Line 38: | Line 32: | ||
===== Clinical Presentation ===== | ===== Clinical Presentation ===== | ||
- | |||
- | ---- | ||
**CNS effects: | **CNS effects: | ||
Line 46: | Line 38: | ||
===== Management ===== | ===== Management ===== | ||
- | |||
- | ---- | ||
The main priorities in management are treatment of muscarinic effects and airway management. For advice regarding specific agents, see the relevant monograph. | The main priorities in management are treatment of muscarinic effects and airway management. For advice regarding specific agents, see the relevant monograph. |